[go: up one dir, main page]

NO20070174L - Preparations and methods for the prevention and control of insulin-induced hypoglycemia - Google Patents

Preparations and methods for the prevention and control of insulin-induced hypoglycemia

Info

Publication number
NO20070174L
NO20070174L NO20070174A NO20070174A NO20070174L NO 20070174 L NO20070174 L NO 20070174L NO 20070174 A NO20070174 A NO 20070174A NO 20070174 A NO20070174 A NO 20070174A NO 20070174 L NO20070174 L NO 20070174L
Authority
NO
Norway
Prior art keywords
insulin
preparations
control
prevention
methods
Prior art date
Application number
NO20070174A
Other languages
Norwegian (no)
Inventor
Daniel T Green
Robert R Henry
Original Assignee
Diobex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex Inc filed Critical Diobex Inc
Publication of NO20070174L publication Critical patent/NO20070174L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives farmasøytiske preparater omfattende både insulin og glukagon. Slike preparater kan administreres for å kontrollere og å behandle diabetes mens samtidig risikoen for insulinindusert hypoglykemi kan reduseres eller elimineres.Pharmaceutical preparations comprising both insulin and glucagon are disclosed. Such preparations can be administered to control and treat diabetes while at the same time reducing or eliminating the risk of insulin-induced hypoglycemia.

NO20070174A 2004-06-29 2007-01-10 Preparations and methods for the prevention and control of insulin-induced hypoglycemia NO20070174L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (1)

Publication Number Publication Date
NO20070174L true NO20070174L (en) 2007-03-13

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070174A NO20070174L (en) 2004-06-29 2007-01-10 Preparations and methods for the prevention and control of insulin-induced hypoglycemia

Country Status (11)

Country Link
EP (1) EP1778266A4 (en)
JP (1) JP2008505087A (en)
KR (1) KR20070029276A (en)
CN (1) CN101001638A (en)
AU (1) AU2005260025A1 (en)
CA (1) CA2571030A1 (en)
IL (1) IL180361A0 (en)
MX (1) MXPA06014970A (en)
NO (1) NO20070174L (en)
WO (1) WO2006004696A2 (en)
ZA (1) ZA200700708B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816114C (en) 2010-11-03 2019-02-12 Jan Jezek Novel composition comprising glucagon
JP7001584B2 (en) * 2015-09-04 2022-01-19 ラティチュード ファーマシューティカルズ インコーポレイテッド Stabilized glucagon solution
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
JP7133229B2 (en) * 2017-02-03 2022-09-08 ヴァンダービルト ユニバーシティー Systems, compositions and methods for treating diabetes
EP3651788A1 (en) * 2017-07-14 2020-05-20 Xeris Pharmaceuticals, Inc. Methods for treating congenital hyperinsulinism
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
JP2023533129A (en) * 2020-06-26 2023-08-02 ゼリス ファーマシューティカルズ インコーポレイテッド Stable Sustained-Release Therapeutic Compositions in Polar Aprotic Solvents and Methods of Making Same
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
AU2003274601A1 (en) * 2002-11-18 2004-06-15 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Also Published As

Publication number Publication date
WO2006004696A3 (en) 2006-10-26
CA2571030A1 (en) 2006-01-12
KR20070029276A (en) 2007-03-13
JP2008505087A (en) 2008-02-21
CN101001638A (en) 2007-07-18
IL180361A0 (en) 2007-06-03
WO2006004696A2 (en) 2006-01-12
EP1778266A4 (en) 2009-09-09
MXPA06014970A (en) 2007-03-07
AU2005260025A1 (en) 2006-01-12
EP1778266A2 (en) 2007-05-02
ZA200700708B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20053537L (en) Preparations and methods for the prevention and control of insulin-induced hypoglycemia.
NO20070174L (en) Preparations and methods for the prevention and control of insulin-induced hypoglycemia
Malone et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
NO340679B1 (en) Pyridazine derivatives, pharmaceutical compositions comprising such and such compounds and preparations for use in therapeutically active substances for the treatment and prevention of diseases
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
NO20054534L (en) Delivery system for drug and cell therapy
WO2020201041A3 (en) Glucose sensitive insulin derivatives
ATE552031T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NON-ACYLATED GHRELIN FOR THE TREATMENT OF INSULIN RESISTANCE
MX2009007723A (en) Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes.
Xu et al. Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats
TNSN08144A1 (en) Kit for parenteral administration of medicaments
Lind Incretin therapy and its effect on body weight in patients with diabetes
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
EA201070557A1 (en) METHODS AND COMPOSITIONS FOR SLOWING UP A WEIGHT KNOB ASSOCIATED WITH ATYPICAL ANTIPSYCHOTIC PREPARATIONS
Mest Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
EP3758689A4 (en) Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients
DK1675611T3 (en) Therapeutic uses for C-peptide
Kulasekararaj et al. Phase 3 study of danicopan, an oral complement factor D inhibitor, as add-on therapy to a C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with clinically evident extravascular hemolysis
NO20075508L (en) Stable Soporphine Preparations and Administration
NO20075831L (en) Crystalline solid and amorphous forms of (-) - halophenate
MD20060037A (en) Method of treating the acute viral hepatitis C
Cohn et al. San Antonio vasopressin in shock symposium report
Mascitelli et al. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence
Xu et al. Acute efficacy of a novel anti-tissue factor pathway inhibitor antibody BAY 1093884 in hemophilia A mouse severe tail bleeding
Tack et al. Pasireotide in dumping syndrome-results from a phase 2, international, multicentre study

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application